Chemokines, soluble PD-L1, and immune cell hyporesponsiveness are distinct features of SARS-CoV-2 critical illness
Authors:
- 24 May 2022
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 323 (1) , L14-L26
Abstract
Critically ill patients manifest many of the same immune features seen in coronavirus disease 2019 (COVID-19), including both “cytokine storm” and “immune suppression.” However, direct comparisons of molecular and cellular profiles between contemporaneously enrolled critically ill patients with and without severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are limited. We sought to identify immune signatures specifically enriched in critically ill patients with COVID-19 compared with patients without COVID-19. We enrolled a multisite prospective cohort of patients admitted under suspicion for COVID-19, who were then determined to be SARS-CoV-2-positive (n = 204) or -negative (n = 122). SARS-CoV-2-positive patients had higher plasma levels of CXCL10, sPD-L1, IFN-γ, CCL26, C-reactive protein (CRP), and TNF-α relative to SARS-CoV-2-negative patients adjusting for demographics and severity of illness (Bonferroni P value < 0.05). In contrast, the levels of IL-6, IL-8, IL-10, and IL-17A were not significantly different between the two groups. In SARS-CoV-2-positive patients, higher plasma levels of sPD-L1 and TNF-α were associated with fewer ventilator-free days (VFDs) and higher mortality rates (Bonferroni P value < 0.05). Lymphocyte chemoattractants such as CCL17 were associated with more severe respiratory failure in SARS-CoV-2-positive patients, but less severe respiratory failure in SARS-CoV-2-negative patients (P value for interaction < 0.01). Circulating T cells and monocytes from SARS-CoV-2-positive subjects were hyporesponsive to in vitro stimulation compared with SARS-CoV-2-negative subjects. Critically ill SARS-CoV-2-positive patients exhibit an immune signature of high interferon-induced lymphocyte chemoattractants (e.g., CXCL10 and CCL17) and immune cell hyporesponsiveness when directly compared with SARS-CoV-2-negative patients. This suggests a specific role for T-cell migration coupled with an immune-checkpoint regulatory response in COVID-19-related critical illness.Keywords
Funding Information
- Bill and Melinda Gates Foundation
- Firland Foundation
- HHS | CDC | National Center for Emerging and Zoonotic Infectious Diseases
- HHS | NIH | National Heart, Lung, and Blood Institute (K23HL144916)
- HHS | NIH | National Heart, Lung, and Blood Institute (F32HL 158088)
- HHS | NIH | National Heart, Lung, and Blood Institute (R03HL141523)
- HHS | NIH | National Heart, Lung, and Blood Institute (R01HL149676)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (K08AI119142)
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (K23DK116967)
This publication has 74 references indexed in Scilit:
- Initial Trophic vs Full Enteral Feeding in Patients With Acute Lung Injury: The EDEN Randomized TrialJAMA, 2012
- Immunosuppression in Patients Who Die of Sepsis and Multiple Organ FailureJAMA, 2011
- A genomic storm in critically injured humansJournal of Experimental Medicine, 2011
- Randomized, Placebo-controlled Clinical Trial of an Aerosolized β2-Agonist for Treatment of Acute Lung InjuryAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Eight-Year Trend of Acute Respiratory Distress Syndrome: A Population-based Study in Olmsted County, MinnesotaAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Endotoxin tolerance: new mechanisms, molecules and clinical significanceTrends in Immunology, 2009
- Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2000
- Outcomes Research in Critical Care: Results of the American Thoracic Society Critical Care Assembly Workshop on Outcomes ResearchAmerican Journal of Respiratory and Critical Care Medicine, 1999
- Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care unitsCritical Care Medicine, 1998
- The APACHE III Prognostic SystemChest, 1991